[{"orgOrder":0,"company":"VectorBuilder","sponsor":"Lantu Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"LTGT06","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"VectorBuilder","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VectorBuilder \/ Lantu Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"VectorBuilder \/ Lantu Biopharma"},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Legend Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"VectorBuilder","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"VectorBuilder \/ Legend Capital","highestDevelopmentStatusID":"1","companyTruncated":"VectorBuilder \/ Legend Capital"},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Stand Up Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"AAV-Based Gene Therapy","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"VectorBuilder","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"VectorBuilder \/ Stand Up Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"VectorBuilder \/ Stand Up Therapeutics"},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Genetic Immunity","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"Plasmid DNA-based HIV Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"VectorBuilder","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"VectorBuilder \/ Genetic Immunity","highestDevelopmentStatusID":"8","companyTruncated":"VectorBuilder \/ Genetic Immunity"},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Chengdu Yousino Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"UC101","moa":"CD19","graph1":"Immunology","graph2":"IND Enabling","graph3":"VectorBuilder","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"VectorBuilder \/ VectorBuilder","highestDevelopmentStatusID":"5","companyTruncated":"VectorBuilder \/ VectorBuilder"}]